BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose.

The company was founded as a spin-off from the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation, NIH and DOD contracts, BlueWillow’s technology has been advanced significantly in recent years yielding several therapies in development.

Biotechnology

BlueWillow Biologics

Chad Costley

Lawrence Black

Cqt Hugo Acosta

Stephen Gracon

Kishna Kalicharran

George Arida

The Research and Development team at BlueWillow Biologics is dedicated to innovation in nanotechnology-based healthcare solutions. They focus on creating and testing topical antiseptic and anti-infective products, as well as intranasal vaccines, leveraging expertise in formulation and clinical applications. By collaborating on research projects and conducting rigorous laboratory experiments, the team aims to advance therapies that meet critical medical needs.

Research and Development

About

Team members